152 related articles for article (PubMed ID: 36574540)
1. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
Vercruyssen J; Meeus P; Bailleul E
Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
[TBL] [Abstract][Full Text] [Related]
2. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
3. Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon.
Frans G; Meeus P; Bailleul E
J Thromb Haemost; 2019 Aug; 17(8):1354-1362. PubMed ID: 31102433
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
Ząbczyk M; Natorska J; Kopytek M; Malinowski KP; Undas A
Arch Pathol Lab Med; 2021 Jan; 145(1):99-104. PubMed ID: 33367661
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
6. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
7. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples.
Sevenet PO; Cucini V; Hervé T; Depasse F; Carlo A; Contant G; Mathieu O
Int J Lab Hematol; 2020 Oct; 42(5):636-642. PubMed ID: 32567799
[TBL] [Abstract][Full Text] [Related]
10. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
11. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
12. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
13. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays.
Exner T; Rigano J; Favaloro EJ
Int J Lab Hematol; 2020 Jun; 42 Suppl 1():41-48. PubMed ID: 32543072
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
[TBL] [Abstract][Full Text] [Related]
16. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
17. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
18. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
Volod O; Rollins-Raval M; Goodwin AJ; Higgins RA; Long T; Chandler WL; Harris NS; Pham HP; Isom JA; Moser K; Olson JD; Smock KJ; VanSandt A; Wool G; Chen D
Arch Pathol Lab Med; 2022 Jan; 146(2):145-153. PubMed ID: 34133726
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Siriez R; Dogné JM; Gosselin R; Laloy J; Mullier F; Douxfils J
Int J Lab Hematol; 2021 Feb; 43(1):7-20. PubMed ID: 32946681
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
De Kesel PM; Devreese KMJ
J Thromb Haemost; 2020 Aug; 18(8):2003-2017. PubMed ID: 32400112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
